KITE 718

Drug Profile

KITE 718

Alternative Names: KITE-718

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kite Pharma
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; MAGEA-3-protein-modulators; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Aug 2017 Interim efficacy data from a phase I trial in Solid tumours (Late stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) released by Kite Pharma
  • 08 May 2017 Phase I clinical trials in Solid tumours (Late stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) in USA (IV) (Kite Pharma pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top